Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Ruxolitinib-Based Primary Treatment for Acute GVHD

NCT06936566 is registered in ClinicalTrials.gov with John Levine as lead sponsor.

NCT NCT06936566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06936566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Ruxolitinib-Based Primary Treatment for Acute GVHD
Lead sponsor
John Levine
Phase
Phase 2
Overall status
Recruiting
Start date
May 14, 2025
Completion date
April 14, 2028
Enrollment
98 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute graft-versus-host disease, adverse effects, allogeneic bone marrow transplantation